TScan Therapeutics, Inc.
Public company- Headquarters
- WALTHAM, Massachusetts
- Industry
- Biotechnology
- Ticker
- TCRX
- CIK
- 0001783328
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| DirectorGarry Nicholson | Oct 16, 2026 | Departed |
| memberStephen Biggar | Oct 16, 2026 | Appointed |
| chairpersonR. Keith Woods | Oct 16, 2026 | Appointed |
| CFOJason A. Amello | Sep 2, 2026 | Departed |
| CMOChrystal Louis, M.D., MPH | Sep 2, 2026 | Departed |
| CEOGavin MacBeath, Ph.D. | Sep 2, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- Eloxx Pharmaceuticals, Inc.
director appointed: Geno J. Germano
- Voyager Therapeutics, Inc.
president appointed: Robin Swartz
- Moderna, Inc.
COO appointed: Juan Andres
- REPLIGEN CORP
Board of Directors departs: Karen A. Dawes
- Executive departure
Director departs: Garry Nicholson
Garry Nicholson, Director of TScan Therapeutics, Inc., resigns the role, effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 16, 2026Role: Director
- Executive departure
Director departs: Gabriela Gruia, M.D.
Gabriela Gruia, M.D., Director of TScan Therapeutics, Inc., resigns the role, effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 16, 2026Role: Director
- Executive appointment
member appointed: Stephen Biggar
Stephen Biggar was named member of TScan Therapeutics, Inc., effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 16, 2026Role: member
- Executive appointment
chairperson appointed: R. Keith Woods
R. Keith Woods was named chairperson of TScan Therapeutics, Inc., effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 16, 2026Role: chairperson
- Executive departure
CFO departs: Jason A. Amello
Jason A. Amello, Chief Financial Officer of TScan Therapeutics, Inc., leaves the role, effective September 2, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 2, 2026Role: Chief Financial Officer
- Executive departure
CMO departs: Chrystal Louis, M.D., MPH
Chrystal Louis, M.D., MPH, Chief Medical Officer of TScan Therapeutics, Inc., leaves the role, effective September 2, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 2, 2026Role: Chief Medical Officer
- Executive appointment
CEO appointed: Gavin MacBeath, Ph.D.
Gavin MacBeath, Ph.D. was named Chief Executive Officer of TScan Therapeutics, Inc., effective September 2, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 2, 2026Role: Chief Executive Officer
layoffs from Nov 2, 2026
WARN noticeWARN notice: Waltham, MA, MA
TScan Therapeutics Inc. (dba TScan) filed a WARN notice with the Massachusetts WARN list covering 96 workers in Waltham, MA. The layoffs take effect on Nov 2, 2026.
Source: Massachusetts WARN list, filed Sep 2, 2026Site: Waltham, MA, MA
Workers affected: 96
Last verified Nov 8, 2026